Sojournix, Inc.

Biotechnology ResearchMassachusetts, United States11-50 Employees

Sojournix is a clinical stage biopharmaceutical company focused on developing and commercializing novel therapies for the treatment of women’s health and neuroendocrine disorders. 

We are developing SJX-653, a novel and selective neurokinin-3 (NK3) antagonist as a once-daily non-hormonal therapy for moderate to severe vasomotor symptoms (or “hot flashes”) due to menopause. 

Prevalent among menopausal women, vasomotor symptoms (VMS) are characterized by sudden and recurrent sensations of intense heat or “hot flashes,” often accompanied by elevated heart rate, hidrosis (sweating), erythema (skin reddening), and the disruption of daily activities and sleep. An estimated 6,000 U.S. women reach menopause every day (over two million per year) and the majority of these women experience vasomotor symptoms. The median duration of vasomotor symptoms is approximately 7 years, while some women experience symptoms for much longer.

While hormone therapy is highly effective for treating VMS, FDA labels for hormone therapy products contain boxed warnings highlighting potential safety risks related to breast cancer, stroke, dementia, and other concerns. Available non-hormonal agents, such as selective serotonin reuptake inhibitors’ (SSRI) anti-depressants, have limited efficacy. We believe SJX-653 has the potential to address the high unmet medical need for a safe and effective non-hormonal therapy for menopausal VMS.

Sojournix controls global development and commercialization rights for SJX-653 and we have raised $70 million from leading healthcare investors.

Sign up for free to view info

Email Format Employee directory